Baird raised the firm’s price target on Medpace (MEDP) to $362 from $354 and keeps a Neutral rating on the shares. The firm preiovewed its Q4 results and guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks